Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome

Abstract

ClinicalTrials.gov:NCT01952080; EudraCT: 2013-004588-30.

Pediatric Intestinal Failure: The Key Outcomes for the First 100 Patients Treated in a National Tertiary Referral Center During 1984–2017

“…Prematurity strongly associated in this study with the achievement of enteral autonomy in SBS, highlighting the intestinal growth and adaption potential in premature babies, as well as the use of age‐adjusted small‐bowel length for analytical purposes . Recently, novel medical agents promoting intestinal adaptation have emerged and may continue to improve the outlook for patients with SBS with the shortest remaining small bowel …”

“…31 Recently, novel medical agents promoting intestinal adaptation have emerged and may continue to improve the outlook for patients with SBS with the shortest remaining small bowel. 5,6 In this study, congenital intestinopathies represented a minority with variable rare diseases leading to IF. Although the underlying genetic defect was discovered for most, congenital intestinopathy diagnoses typically associated with IF were not observed, probably because of the genetic isolation of the Finnish population.…”

“…Pediatric intestinal failure (IF) causes significant morbidity and mortality, affecting neonates and young children during their vulnerable period of somatic, neurological, and psychological development. Recent advances in IF care have shown encouraging results with IF-associated liver disease (IFALD) through parenterally administered lipid modifications, [1][2][3][4] as to accelerated rate of weaning off parenteral nutrition (PN) using pharmacological agents 5,6 and increased transplant-free survival in dedicated intestinal rehabilitation centers. [7][8][9][10][11][12] Unfortunately, many of these positive trends may only pertain to the major cause of IF, short bowel syndrome (SBS).…”

Nutritional therapy complications in children with ultra‐short bowel syndrome include growth deficiency but not cholestasis

“…Studies with glucagon‐like peptide 1 (GLP2) analogue (teduglutide) in adults with SBS showed enhanced intestinal adaptation, a diminished need for parenteral support, an increased absorptive capacity of the remnant intestine and increased plasma concentrations of citrulline, which is a biomarker of mucosal mass . The safety and usefulness of teduglutide therapy in children with SBS were assessed, and the results showed that the PN requirement was reduced and increased enteral feeding was observed . The citrulline concentration seemed to be a good marker for monitoring during intestinal rehabilitation treatment, but its role in USBS was not fully elucidated.…”

Dose‐dependent elevation in amylase and lipase in response to teduglutide administration

“…Other studies have demonstrated a variety of side effects including an increase in lean body mass and pancreatic enzymes . The increase in pancreatic enzymes has been demonstrated in few reports, including one study examining pediatric short bowel syndrome where a dose‐dependent increase of amylase was found in response to varying levels of GLP‐2 analogue administration . In this case report, an adult patient with a dose‐dependent increase of amylase levels with the administration of teduglutide (GLP‐2 analogue) will be described.…”